Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,481 to 1,500 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition. | Cell Death Dis | 2021 | 34482362 | PubTator, text mining | PubMed |
| Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer. | J Med Chem | 2021 | 34473519 | PubTator, text mining | PubMed |
| A Chemical Toolbox for Labeling and Degrading Engineered Cas Proteins. | JACS Au | 2021 | 34467332 | PubTator, text mining | PubMed |
| Potential Role of Pleural Fluid Cytokine Profile in Myelomatous Pleural Effusions. | Onco Targets Ther | 2021 | 34466000 | PubTator, text mining | PubMed |
| Ribosomal proteins and human diseases: molecular mechanisms and targeted therapy. | Signal Transduct Target Ther | 2021 | 34462428 | PubTator, text mining | PubMed |
| Fragment-based covalent ligand discovery. | RSC Chem Biol | 2021 | 34458789 | PubTator, text mining | PubMed |
| Selective degradation-inducing probes for studying cereblon (CRBN) biology. | RSC Med Chem | 2021 | 34458741 | PubTator, text mining | PubMed |
| Involvement of EZH2 inhibition in lenalidomide and pomalidomide-mediated growth suppression in HTLV-1-infected cells. | Biochem Biophys Res Commun | 2021 | 34455369 | PubTator, text mining | PubMed |
| Quantitative Systems Pharmacology Modeling of Avadomide-Induced Neutropenia Enables Virtual Clinical Dose and Schedule Finding Studies. | AAPS J | 2021 | 34453265 | PubTator, text mining | PubMed |
| Peptide Stapling Improves the Sustainability of a Peptide-Based Chimeric Molecule That Induces Targeted Protein Degradation. | Int J Mol Sci | 2021 | 34445478 | PubTator, text mining | PubMed |
| Immunomodulatory Drugs for the Treatment of B Cell Malignancies. | Int J Mol Sci | 2021 | 34445275 | PubTator, text mining | PubMed |
| The Ups and Downs of STAT Inhibition in Acute Myeloid Leukemia. | Biomedicines | 2021 | 34440253 | PubTator, text mining | PubMed |
| Therapeutic Advances Propelled by Deciphering Tumor Biology and Immunology-Highlights of the 8th Heidelberg Myeloma Workshop. | Cancers (Basel) | 2021 | 34439297 | PubTator, text mining | PubMed |
| The Impact of Induction Regimes on Immune Responses in Patients with Multiple Myeloma. | Cancers (Basel) | 2021 | 34439244 | PubTator, text mining | PubMed |
| Novel Approaches to Treating Relapsed and Refractory Multiple Myeloma with a Focus on Recent Approvals of Belantamab Mafodotin and Selinexor. | Clin Pharmacol | 2021 | 34434061 | PubTator, text mining | PubMed |
| Profiling CELMoD-Mediated Degradation of Cereblon Neosubstrates. | Methods Mol Biol | 2021 | 34432250 | PubTator, text mining | PubMed |
| A High-Throughput Method to Prioritize PROTAC Intracellular Target Engagement and Cell Permeability Using NanoBRET. | Methods Mol Biol | 2021 | 34432249 | PubTator, text mining | PubMed |
| Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells. | Methods Mol Biol | 2021 | 34432243 | PubTator, text mining | PubMed |
| Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer. | J Med Chem | 2021 | 34431670 | PubTator, text mining | PubMed |
| Exploring Ligand-Directed N-Acyl-N-alkylsulfonamide-Based Acylation Chemistry for Potential Targeted Degrader Development. | ACS Med Chem Lett | 2021 | 34413960 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=75